ASAM Pocket Guidelines and Patient Guide

ASAM Opioid Patient Guide 2020

ASAM Opioid Addiction Treatment GUIDELINES Apps and Pocket Guides brought to you courtesy of Guideline Central. Enjoy!

Issue link:

Contents of this Issue


Page 6 of 19

7 MEDICATIONS TO TREAT OPIOID ADDICTION Medication Brand Names Buprenorphine Sublocade® (Injection), Brixadi® (injection), Probuphine® (implant), generics (films or tablets) Buprenorphine and naloxone Bunavail®, Cassipa®, Suboxone®, Zubsolv®, generics (films or tablets) Methadone generics (liquid or tablets to dissolve in water) Extended release naltrexone Vivitrol® (injection) WITHDRAWAL • Opioid withdrawal refers to the wide range of painful and unpleasant symptoms that occur after stopping or cutting down on the use of opioids. Withdrawal can last more than 10 days but is most often between 3–5 days. • Although it can cause very troubling symptoms (such as vomiting, cramps and sweating), opioid withdrawal is rarely life-threatening. • Using medications to control withdrawal (also called withdrawal management) is almost always recommended over trying to endure withdrawal without treatment. When patients do try to stop using opioids without treatment it can lead to stronger cravings and continued use. • Withdrawal management on its own is not a treatment for opioid addiction and may increase the risk of relapse, overdose, and overdose death. • When treating someone for opioid addiction, medication (methadone, buprenorphine, or naltrexone) in combination with counseling and other support is usually recommended. • Lofexidine and clonidine are safe and effective for management of opioid withdrawal, but methadone and buprenorphine are more effective and can be continued for the treatment of opioid addiction. • Opioid withdrawal management using ultra-rapid opioid detoxification (UROD) is not recommended due to high risk for adverse events including death.

Articles in this issue

view archives of ASAM Pocket Guidelines and Patient Guide - ASAM Opioid Patient Guide 2020